If you typed Biointelect into a search box, you are probably building a CRO shortlist. This article uses only what Biointelect publishes (www.biointelect.com/cro) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Biointelect publishes
Biointelect is a Sydney consultancy founded in 2011 that added a CRO. It lists medical devices among its therapeutic areas, plus first-in-human, Phase I–II and high-risk inpatient studies, and leans toward strategy, local sponsor and regulatory work. Leah Goodman is CEO.
Biointelect vs bioaccess®
| Dimension | Biointelect | bioaccess® |
|---|---|---|
| Core focus | Australian consulting + CRO + local sponsor | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If what you need is an Australian entity, local sponsor and R&D tax-incentive coordination around a Phase I unit, Biointelect fits.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Biointelect, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Biointelect features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Biointelect public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply